Fennec Pharmaceuticals Inc (NASDAQ: FENC) stock enjoyed a major increase of 11.6% on 10/28/24. The shares closed at $4.73. However, trading volume in this advance was unusually low at 61% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 4.2% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, FENC is expected to be Value Creation neutral.
Fennec Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment